3 results
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
1) To evaluate the efficacy of knee-ankle-foot orthoses (worn by night) in preventing a decrease of range of motion to ankle dorsiflexion in children with cerebral palsy (Clinical part). 2) To evaluate the effect of night-worn knee-ankle-foot…
Primary objective: The primary objective is to assess the efficacy and safety of nemolizumab (CD14152) after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…